Last reviewed · How we verify
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine is a Combination chemotherapy with anti-angiogenic monoclonal antibody Small molecule drug developed by Borstkanker Onderzoek Groep. It is currently in Phase 3 development for Metastatic breast cancer (likely indication given Borstkanker Onderzoek Groep focus on breast cancer). Also known as: Non-pegylated liposomal doxorubicin (Myocet®), Non-pegylated liposomal doxorubicin (Myocet®):.
This combination regimen uses multiple chemotherapy agents and an anti-angiogenic antibody to kill cancer cells through distinct mechanisms: microtubule stabilization, vascular disruption, DNA intercalation, and antimetabolite activity.
This combination regimen uses multiple chemotherapy agents and an anti-angiogenic antibody to kill cancer cells through distinct mechanisms: microtubule stabilization, vascular disruption, DNA intercalation, and antimetabolite activity. Used for Metastatic breast cancer (likely indication given Borstkanker Onderzoek Groep focus on breast cancer).
At a glance
| Generic name | Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine |
|---|---|
| Also known as | Non-pegylated liposomal doxorubicin (Myocet®), Non-pegylated liposomal doxorubicin (Myocet®): |
| Sponsor | Borstkanker Onderzoek Groep |
| Drug class | Combination chemotherapy with anti-angiogenic monoclonal antibody |
| Target | Multiple: microtubules (paclitaxel), VEGF (bevacizumab), DNA (doxorubicin), thymidylate synthase (capecitabine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel stabilizes microtubules to prevent cell division. Bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis and vascular supply. Liposomal doxorubicin intercalates DNA to cause strand breaks and cell death. Capecitabine is a prodrug converted to 5-FU, which inhibits thymidylate synthase and disrupts nucleotide synthesis. Together, these agents provide synergistic cytotoxic and anti-angiogenic effects.
Approved indications
- Metastatic breast cancer (likely indication given Borstkanker Onderzoek Groep focus on breast cancer)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Mucositis
- Diarrhea
- Hand-foot syndrome
- Hypertension
- Cardiotoxicity
- Bleeding/thrombotic events
Key clinical trials
- Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- QUILT-3.088: NANT Pancreatic Cancer Vaccine (PHASE2)
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (PHASE1)
- 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer (PHASE3)
- Breast Cancer Treatment Based on Organ-like Culture
- A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine CI brief — competitive landscape report
- Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine updates RSS · CI watch RSS
- Borstkanker Onderzoek Groep portfolio CI
Frequently asked questions about Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
What is Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine?
How does Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine work?
What is Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine used for?
Who makes Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine?
Is Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine also known as anything else?
What drug class is Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine in?
What development phase is Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine in?
What are the side effects of Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine?
What does Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine target?
Related
- Drug class: All Combination chemotherapy with anti-angiogenic monoclonal antibody drugs
- Target: All drugs targeting Multiple: microtubules (paclitaxel), VEGF (bevacizumab), DNA (doxorubicin), thymidylate synthase (capecitabine)
- Manufacturer: Borstkanker Onderzoek Groep — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic breast cancer (likely indication given Borstkanker Onderzoek Groep focus on breast cancer)
- Also known as: Non-pegylated liposomal doxorubicin (Myocet®), Non-pegylated liposomal doxorubicin (Myocet®):
- Compare: Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine vs similar drugs
- Pricing: Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine cost, discount & access